Journal of the American Society of Hypertension
Volume 2, Issue 5 , Pages 341-348 , September 2008

Reduced isoproterenol-induced renin-angiotensin changes and extracellular matrix deposition in hearts of TGR(A1–7)3292 rats

  • Ana Paula Nadu, PhD

      Affiliations

    • Department of Physiology and Biophysics, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil
    • ,
  • Anderson J. Ferreira, PhD

      Affiliations

    • Department of Morphology, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil
    • ,
  • Timothy L. Reudelhuber, PhD

      Affiliations

    • Laboratory of Molecular Biochemistry of Hypertension, Clinical Research Institute of Montreal, Quebec, Canada
    • ,
  • Michael Bader, PhD

      Affiliations

    • Max-Delbrück Center for Molecular Medicine, Berlin-Buch, Germany
    • ,
  • Robson A.S. Santos, MD

      Affiliations

    • Department of Physiology and Biophysics, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil
    • Corresponding Author InformationCorresponding author: Robson A. S. Santos, MD, Departamento de Fisiologia e Biofísica, Av. Antônio Carlos, 6627 – ICB – UFMG, 31.270-901 – Belo Horizonte, MG, Brazil. Tel: (55-31) 3499 2957; fax: (55-31) 3499 2924

Received 24 February 2008 ,Accepted 17 April 2008.

References 

  1. Lijnen PJ, Petrov VV. Role of intracardiac renin-angiotensin-aldosterone system in extracellular matrix remodeling. Methods Find Exp Clin Pharmacol. 2003;25:541–564
  2. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium (Fibrosis and renin-angiotensin-aldosterone system). Circulation. 1991;83:1849–1865
  3. Santos RAS, Castro CH, Gava E, Pinheiro SV, Almeida AP, Paula RD, et al. Impairment of in vitro and in vivo heart function in angiotensin-(1–7) receptor Mas knockout mice. Hypertension. 2006;47:996–1002
  4. Santos RAS, Ferreira AJ, Pinheiro SV, Sampaio WO, Touyz R, Campagnole-Santos MJ. Angiotensin-(1–7) and its receptor as a potential targets for new cardiovascular drugs. Expert Opin Investig Drugs. 2005;14:1019–1031
  5. Ferreira AJ, Santos RAS, Almeida AP. Angiotensin-(1–7): cardioprotective effect in myocardial ischemia/reperfusion. Hypertension. 2001;38:665–668
  6. Grobe JL, Mecca AP, Lingis M, Shenoy V, Bolton TA, Machado JM, et al. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1–7). Am J Physiol Heart Circ Physiol. 2007;292:H736–H742
  7. Loot AE, Roks AJM, Henning RH, Tio RA, Suurmeijer AJH, Boomsma F, et al. Angiotensin-(1–7) attenuates the development of heart failure after myocardial infarction in rats. Circulation. 2002;105:1548–1550
  8. Ferreira AJ, Jacoby BA, Araujo CA, Macedo FA, Silva GAB, Almeida AP, et al. The nonpeptide angiotensin-(1–7) receptor Mas agonist AVE 0991 attenuates heart failure induced by myocardial infarction. Am J Physiol Heart Circ Physiol. 2007;292:H1113–H1119
  9. Ferreira AJ, Santos RAS, Almeida AP. Angiotensin-(1–7) improves the post-ischemic function in isolated perfused rat hearts. Braz J Med Biol Res. 2002;35:1083–1090
  10. Tallant EA, Ferrario CM, Gallagher PE. Angiotensin-(1–7) inhibits growth of cardiac myocytes through activation of the Mas receptor. Am J Physiol Heart Circ Physiol. 2005;289:H1560–H1566
  11. Santos RAS, Simões e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, et al. Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A. 2003;100:8258–8263
  12. Iwata M, Cowling RT, Gurantz D, Moore C, Zhang S, Yuan JX, et al. Angiotensin-(1–7) binds to specific receptors on cardiac fibroblasts to initiate anti-fibrotic and anti-trophic effects. Am J Physiol Heart Circ Physiol. 2005;289:H2356–H2363
  13. Castro CH, Santos RAS, Ferreira AJ, Bader M, Alenina N, Almeida AP. Effects of genetic deletion of angiotensin-(1–7) receptor Mas on cardiac function during ischemia/reperfusion in the isolated perfused mouse heart. Life Sci. 2006;80:264–268
  14. Grobe JL, Mecca AP, Mao H, Katovich MJ. Chronic angiotensin-(1–7) prevents cardiac fibrosis in DOCA-salt model of hypertension. Am J Physiol Heart Circ Physiol. 2006;290:H2417–H2423
  15. Santos RAS, Ferreira AJ, Nadu AP, Braga ANG, Almeida AP, Campagnole-Santos MJ, et al. Expression of an angiotensin-(1–7)-producing fusion protein produces cardioprotective effects in rats. Physiol Genomics. 2004;17:292–299
  16. Botelho-Santos GA, Sampaio WO, Reudelhuber TL, Bader M, Campagnole-Santos MJ, Santos RAS. Expression of an angiotensin-(1–7)-producing fusion protein in rats induced marked changes in regional vascular resistance. Am J Physiol Heart Circ Physiol. 2007;292:H2485–H2490
  17. Botelho LMO, Block CH, Khosla MC, Santos RAS. Plasma angiotensin-(1–7) immunoreactivity is increased by salt load, water deprivation, and hemorrhage. Peptides. 1994;15:723–729
  18. Bradford MM. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–254
  19. Benter IF, Yousif MH, Anim JT, Cojocel C, Diz DI. Angiotensin-(1–7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME. Am J Physiol Heart Circ Physiol. 2006;290:H684–H691
  20. Diez-Freire C, Vazquez J, Correa de Adjounian MF, Ferrari MF, Yuan L, Silver X, et al. ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. Physiol Genomics. 2006;27:12–19
  21. Ferreira AJ, Oliveira TL, Castro MC, Almeida AP, Castro CH, Caliari MV, et al. Isoproterenol-induced impairment of heart function and remodeling are attenuated by the nonpeptide angiotensin-(1–7) analogue AVE 0991. Life Sci. 2007;81:916–923
  22. Pan CH, Wen CH, Lin CS. Interplay of angiotensin II and angiotensin-(1–7) in the regulations of matrix metalloproteinases of human cardiocytes. Exp Physiol. 2008;93:599–612
  23. Mendes AC, Ferreira AJ, Pinheiro SV, Santos RAS. Chronic infusion of angiotensin-(1–7) reduces heart angiotensin II levels in rats. Regul Pept. 2005;125:29–34
  24. Reudelhuber TL, Bernstein KE, Delafontaine P. Is angiotensin II a direct mediator of left ventricular hypertrophy? (Time for another look). Hypertension. 2007;49:1196–1201
  25. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004;43:970–976
  26. Ocaranza MP, Godoy I, Jalil JE, Varas M, Collantes P, Pinto M, et al. Enalapril attenuates downregulation of angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat. Hypertension. 2006;48:572–578

 This work was supported by CNPq-PRONEX (Conselho Nacional de Desenvolvimento Científico e Tecnológico), FAPEMIG-PRONEX (Fundação de Amparo à Pesquisa de Minas Gerais), and CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior).

 Conflict of interest: none.

PII: S1933-1711(08)00075-2

doi: 10.1016/j.jash.2008.04.012

Journal of the American Society of Hypertension
Volume 2, Issue 5 , Pages 341-348 , September 2008

Article Tools

* Image Usage & Resolution